# AZD9291 in Combination With Ascending Doses of Novel Therapeutics

> **NCT02143466** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 344 (actual)

## Conditions studied

- Advanced Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Part A - AZD9291 in combination with AZD6094
- **DRUG:** Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)
- **DRUG:** Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
- **DRUG:** Part A - AZD9291 in combination with intermittent selumetinib
- **DRUG:** Part A - AZD9291 in combination with MEDI4736
- **DRUG:** Part B - AZD9291 in combination with AZD6094
- **DRUG:** Part B - AZD9291 in combination with selumetinib
- **DRUG:** Part B - AZD9291 in combination with MEDI4736
- **DRUG:** Part C - AZD6094 monotherapy (Japan only)
- **DRUG:** Part C - AZD9291 in combination with AZD6094 (Japan only)
- **DRUG:** Part D - AZD9291 in combination with AZD6094

## Key facts

- **NCT ID:** NCT02143466
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-08-05
- **Primary completion:** 2020-03-04
- **Final completion:** 2026-12-31
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02143466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02143466, "AZD9291 in Combination With Ascending Doses of Novel Therapeutics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02143466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*